Development of N -methyl-(2-arylquinolin-4-yl)oxypropanamides as leads to PET radioligands for translocator protein (18 kDa)

Journal of Medicinal Chemistry

Volumn 57, Issue 14, 2014, Pages 6240-6251

  Brouwer, Chad ^a   Jenko, Kimberly ^a   Zoghbi, Sami S ^a   Innis, Robert B ^a   Pike, Victor W ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

,N2 DIMETHYL 3 (2 PHENYLQUINOLIN 4 YL)PROPANAMIDE; 1 METHY 3 [(2 PHENYLQUINOLIN 4 YL)METHYL]PYRROLIDIN 2 ONE; 2 PHENYL 1,4 DIHYDRO 1,5 NAPHTHYRIDIN 4 ONE; 2 PHENYL 1,4 DIHYDROQUINAZOLIN 4 ONE; CARRIER PROTEIN; N (3 BROMOPYRIDIN 2 YL)BENZAMIDE; N (3 BROMOPYRIDIN 4 YL)BENZAMIDE; N (BUTAN 2 YL) N,2 DIMETHYL 3 (2 PHENYLQUINOLIN 4 YLPROPANAMIDE; N BENZYL N,2 DIMETHYL 3 (2 PHENYLQUINOLIN 4 YL)PROPANAMIDE; N BUTYL N,2 DIMETHYL 3 (2 PHENYLQUINOLIN 4 YL) N PROPYLPROPANAMIDE; N ETHYL N,2 DIMETHYL 3 (2 PHENYLQUINOLIN 4 YL)PROPANAMIDE; N METHYL (2 ARYLQUINOLIN 4 YL)OXYPROPANAMIDE; N METHYL N PHENYL 2 SULFANYLPROPANAMIDE; N METHYL N PHENYL 2 [[2 (PYRIDIN 2 YL)QUINOLIN 4 YL]OXY]PROPANAMIDE; N PHENYL 2 [(2 PHENYLQUINOLIN 4 YL)SULFANYL]PROPANAMIDE; N,2 DIMETHYL 3 (2 PHENYLQUINOLIN 4 YL) N (PROPAN 2 YL)PROPYLPROPANAMIDE; N,2 DIMETHYL 3 (2 PHENYLQUINOLIN 4 YL) N (PYRIDIN 3 YL)PROPANAMIDE; N,2 DIMETHYL 3 (2 PHENYLQUINOLIN 4 YL) N PROPYLPROPANAMIDE; N,2 DIMETHYL 3 (2 PHENYLQUINOLIN 4 YL) N PYRIDIN 2 YL)PROPANAMIDE; N,2 DIMETHYL 3 (2 PHENYLQUINOLIN 4 YL)PROPANAMIDE; N,2 DIMETHYL N (2 METHYLPROPYL) 3 (2 PHENYLQUINOLIN 4 YL)PROPANAMIDE; N,2 DIMETHYL N PENTYL 3 (2 PHENYLQUINOLIN 4 YL) N PROPYLPROPANAMIDE; N,2 DIMETHYL N PHENYL 3 (2 PHENYLQUINOLIN 4YL)PROPANAMIDE; N,N DIETHYL 2 METHYL 3 (2 PHENYLQUINOLIN 4 YL)PROPANAMIDE; N,N DIETHYL 2 [(2 PHENYLQUINOLIN 4 YL)METHYL]BUTANAMIDE; N,N DIETHYL 3 (2 PHENYLQUINOLIN 4 YL)PROPANAMIDE; N,N,2 TRIMETHYL 3 (2 PHENYLQUINOLIN 4 YL)PROPANAMIDE; PROPIONAMIDE DERIVATIVE; RADIOLIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG STRUCTURE; FLUORINE NUCLEAR MAGNETIC RESONANCE; GENOTYPE; HUMAN; HUMAN CELL; LIGAND BINDING; LIPOPHILICITY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN BINDING; RAT; X RAY CRYSTALLOGRAPHY;

ANIMALS; BIOLOGICAL MARKERS; BRAIN; CARBON RADIOISOTOPES; DRUG DESIGN; GENOTYPE; HUMANS; LEUKOCYTES; LIGANDS; MOLECULAR STRUCTURE; POSITRON-EMISSION TOMOGRAPHY; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GABA;

EID: 84904989440     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5007947     Document Type: Article

References (62)

1. Anholt, R. R. H.; De Souza, E. B.; Oster-Granite, M. L.; Snyder, S. H. Peripheral-type benzodiazepine receptors: autoradiographic localization in whole-body sections of neonatal rats J. Pharmacol. Exp. Ther. 1985, 233, 517-526
2. Papadopoulos, V.; Baraldi, M.; Guilarte, T. R.; Knudsen, T. B.; Lacapère, J. J.; Lindemann, P.; Norenberg, M. D.; Nutt, D.; Weizman, A.; Zhang, M.-R.; Gavish, M. Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function Trends Pharmacol. Sci. 2006, 27, 402-409
3. Syapin, P. J.; Skolnick, P. Characterization of benzodiazepine binding sites in cultured cells of neural origin J. Neurochem. 1979, 32, 1047-1051
4. McEnery, M. W.; Snowman, A. M.; Trifiletti, R. R.; Snyder, S. H. Isolation of the mitochondrial benzodiazepine receptor: Association with the voltage-dependent anion channel and the adenine nucleotide carrier Proc. Natl. Acad. Sci. U. S. A. 1992, 89, 3170-3174
5. 3H]PK 11195: anatomical and subcellular distribution Brain Res. Bull. 1987, 18, 49-61
6. Wright, G.; Reichenbecher, V. The effects of superoxide and the peripheral benzodiazepine receptor ligands on the mitochondrial processing of manganese-dependent superoxide dismutase Exp. Cell Res. 1999, 246, 443-450
7. Papadopoulos, V.; Lecanu, L.; Brown, R. C.; Han, Z.; Yao, Z.-X. Peripheral-type benzodiazepine receptor in neurosteroid biosynthesis, neuropathology and neurological disorders Neuroscience 2006, 138, 749-756
8. Taketani, S.; Kohno, H.; Okuda, M.; Furukawa, T.; Tokunaga, R. Induction of peripheral-type benzodiazepine receptors during differentiation of mouse erythroleukemia cells-a possible involvement of these receptors in heme biosynthesis J. Biol. Chem. 1994, 269, 7527-7531
9. Benavides, J.; Fage, D.; Carter, C.; Scatton, B. Peripheral type benzodiazepine binding sites are a sensitive indirect index of neuronal damage Brain Res. 1987, 421, 167-172
10. Cagnin, A.; Gerhard, A.; Banati, R. B. In vivo imaging of neuroinflammation Eur. Neuropsychopharmacol. 2002, 12, 581-586
11. Banati, R. B. Visualising microglial activation in vivo Glia 2002, 40, 206-217
12. 11C]PBR28 can localize and quantify upregulated peripheral benzodiazepine receptors associated with cerebral ischemia in rat Neurosci. Lett. 2007, 411, 200-205
13. Cagnin, A.; Brooks, D. J.; Kennedy, A. M.; Gunn, R. N.; Myers, R.; Turkheimer, F. E.; Jones, T.; Banati, R. B. In vivo measurement of activated microglia in dementia Lancet 2001, 358, 461-467
14. Kreisl, W. C.; Lyoo, C. H.; McGwier, M.; Snow, J.; Jenko, K. J.; Kimura, N.; Corona, W.; Morse, C. L.; Zoghbi, S. S.; Pike, V. W.; McMahon, F. J.; Turner, R. S.; Innis, R. B. Biomarkers Consortium PET Radioligand Project Team. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease Brain 2013, 136, 2228-2238
15. Ouchi, Y.; Yoshikawa, E.; Sekine, Y.; Futatsubashi, M.; Kanno, T.; Ogusu, T.; Torizuka, T. Microglial activation and dopamine terminal loss in early Parkinson's disease Ann. Neurol. 2005, 57, 168-175
16. 11C]PK11195 Eur. J. Neurol. 2003, 10, 257-264
17. Owen, D. R. J.; Matthews, P. M. Imaging brain microglial activation using positron emission tomography and translocator protein-specific radioligands. In Biomarkers of Neurological and Psychiatric Disease; Guest, P. C.; Bahn, S., Eds.; Academic Press: Waltham, MA, 2011; Vol. 101, pp 19-39.
18. Camsonne, R.; Moulin, M. A.; Crouzel, C.; Syrota, A.; Maziere, M.; Comar, D. C-11 Labeling of PK11195 and visualization of peripheral receptors of benzodiazepines by positron-emission tomography J. Pharmacol. 1986, 17, 383
19. 11C]PK 11195 and comparison of their behaviors as radioligands for PK binding sites in rats Nucl. Med. Biol. 1994, 21, 573-581
20. 11C]PK11195 in normal human brain and application in multiple sclerosis patients Acta Neurol. Belg. 2002, 102, 127-135
21. 11C](R)-PK11195 studies J. Cereb. Blood Flow Metab. 2006, 26, 1431-1441
22. 11C]PK11195] and its metabolites in humans Nucl. Med. Biol. 2005, 32, 307-312
23. 11C]PK11195 challengers Eur. J. Nucl. Med. Mol. Imaging 2008, 35, 2304-2319
24. Schweitzer, P. J.; Fallon, B. A.; Mann, J. J.; Kumar, J. S. D. PET tracers for the peripheral benzodiazepine receptor and uses thereof Drug Discovery Today 2010, 15, 933-942
25. Luus, C.; Hanani, R.; Reynolds, A.; Kassiou, M. The development of PET radioligands for imaging the translocator protein (18 kDa): What have we learned? J. Labelled Compd. Radiopharm. 2010, 53, 501-510
26. 11C-labeled aryloxyanilide ligands for imaging brain peripheral benzodiazepine receptors in vivo J. Med. Chem. 2008, 51, 17-30
27. 11C]PBR28: a PET radioligand to image inflammation J. Nucl. Med. 2007, 48, 2072-2079
28. Fujita, M.; Imaizumi, M.; Zoghbi, S. S.; Fujimura, Y.; Farris, A. G.; Suhara, T.; Hong, J.; Pike, V. W.; Innis, R. B. Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation Neuroimage 2008, 40, 43-52
29. 11C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: Implications for positron emission tomographic imaging of this inflammation biomarker Neuroimage 2010, 49, 2924-2932
30. 3H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation J. Cereb. Blood Flow Metab. 2010, 30, 1608-1618
31. Owen, D. R.; Yeo, A. J.; Gunn, R. N.; Song, K.; Wadsworth, G.; Lewis, A.; Rhodes, C.; Pulford, D. J.; Bennacef, I.; Parker, C. A.; StJean, P. L.; Cardon, L. R.; Mooser, V. E.; Matthews, P. M.; Rabiner, E. A.; Rubio, J. P. An 18-kDa Translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28 J. Cereb. Blood Flow Metab. 2012, 32, 1-5
32. Kreisl, W. C.; Jenko, K. J.; Hines, C. S.; Lyoo, C. H.; Corona, W.; Morse, C. L.; Zoghbi, S. S.; Hyde, T.; Kleinman, J. E.; Pike, V. W.; McMahon, F. J.; Innis, R. B.; Biomarkers Consortium, PET Radioligand Project Team. A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation J. Cereb. Blood Flow Metab. 2013, 33, 53-58
33. Owen, D. R. J.; Gunn, R. N.; Rabiner, E. A.; Bennacef, I.; Fujita, M.; Kreisl, W. C.; Innis, R. B.; Pike, V. W.; Reynolds, R.; Matthews, P. M.; Parker, C. A. Mixed-affinity binding in humans with 18-kDa translocator protein ligands J. Nucl. Med. 2011, 52, 24-32
34. 18F]-FEPPA J. Cereb. Blood Flow Metab. 2012, 32, 968-972
35. 1-methyl-2-phenylindol-3-ylglyoxylamides as a new chemotype of 18 kDa translocator protein-selective ligand suitable for the development of positron emission tomography radioligands J. Med. Chem. 2011, 54, 366-373
36. 18F-PBR111 in healthy humans: a genetic polymorphism effect on in vivo binding J. Nucl. Med. 2013, 54, 1915-1923
37. Guo, Q.; Owen, D. R.; Rabiner, E. A.; Turkheimer, F. E.; Gunn, R. N. Identifying improved TSPO PET imaging probes through biomathematics: the impact of multiple TSPO binding sites in vivo NeuroImage 2012, 60, 902-910
38. 3H]PK 11195 to peripheral-type benzodiazepine binding sites by a quinolinepropanamide derivative Eur. J. Pharmacol. 1986, 128, 269-272
39. Pike, V. W. Positron-emitting radioligands for studies in vivo-probes for human psychopharmacology J. Psychopharmacol. 1993, 7, 139-158
40. Laruelle, M.; Slifstein, M.; Huang, Y. Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography Mol. Imaging Biol. 2003, 5, 363-375
41. Patel, S.; Gibson, R. In vivo site-directed radiotracers: a mini-review Nucl. Med. Biol. 2008, 35, 805-815
42. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nature Rev. Drug Discovery 2007, 6, 881-890
43. 2 agonists using parallel synthesis protocols: a lipophilic efficiency (LipE) analysis Bioorg. Med. Chem. Lett. 2009, 19, 4406-4409
44. Shultz, M. D. Setting expectations in molecular optimizations: strengths and limitations of commonly used composite parameters Bioorg. Med. Chem. Lett. 2013, 23, 5980-5991
45. Kuninobu, Y.; Inoue, Y.; Takai, K. Copper(I)- and gold(I)-catalyzed synthesis of 2,4-disubstituted quinoline derivatives from N -aryl-2- propynylamines Chem. Lett. 2007, 36, 1422-1423
46. Frérot, E.; Coste, J.; Pantaloni, A.; Dufour, M.-N.; Jouin, P. PyBOP and PyBroP: two reagents for the difficult coupling of the α,α-dialkyl amino acid, Aib Tetrahedron 1991, 47, 259-270
47. Woodbury, R. P.; Rathke, M. W. Isolation and reactions of α-lithio N, N -dimethylacetamide J. Org. Chem. 1977, 42, 1688-1690
48. VanAllan, J. A. A new process for the preparation of thioglycolylamides J. Am. Chem. Soc. 1947, 69, 2914
49. Wolf, C.; Lerebours, R. Use of highly active palladium-phosphinous acid catalysts in Stille, Heck, amination, and thiation reactions of chloroquinolines J. Org. Chem. 2003, 68, 7077-7084
50. NAr methodology J. Org. Chem. 2007, 72, 2232-2235
51. Knouzi, N.; Vaultier, M.; Carrié, R. Réduction d'azides par la triphénylphosphine en présence d'eau: une méthode générale et chimiosélective d'accès aux amines primaires Bull. Soc. Chim. Fr. 1985, 122, 815-819
52. Winters, R. T.; Sercel, A. D.; Showalter, H. D. H. Efficient synthesis of peri -hydroxylated 9,10-anthracenedione ethers via alkylation of cesium phenolates Synthesis 1988, 712-714
53. Nahm, S.; Weinreb, S. M. N -Methoxy- N -methylamides as effective acylating agents Tetrahedron Lett. 1981, 22, 3815-3818
54. Camps, R. Synthese von α- und γ-oxychinolinen Ber. Dtsch. Chem. Ges. 1899, 32, 3228-3234
55. Jones, C. P.; Anderson, K. W.; Buchwald, S. L. Sequential Cu-catalyzed amidation-base-mediated Camps cyclization: a two-step synthesis of 2-aryl-4-quinolones from o -halophenones J. Org. Chem. 2007, 72, 7968-7973
56. He, Y.; Wang, B.; Dukor, R. K.; Nafie, L. A. Determination of absolute configuration of chiral molecules using vibrational optical activity: a review Appl. Spectrosc. 2011, 65, 699-723
57. Cappelli, A.; Anzini, M.; Vomero, S.; De Benedetti, P. G.; Menziani, M. C.; Giorgi, G.; Manzoni, C. Mapping the peripheral benzodiazepine receptor binding site by conformationally restrained derivatives of 1-(2-chlorophenyl)- N -methyl- N -(1-methylpropyl)-3-isoquinolinecarboxamide (PK11195) J. Med. Chem. 1997, 40, 2910-2921
58. Pike, V. W.; Halldin, C.; Crouzel, C.; Barré, L.; Nutt, D. J.; Osman, S.; Shah, F.; Turton, D. R.; Waters, S. L. Radioligands for PET studies of central benzodiazepine receptors and PK (peripheral benzodiazepine) binding sites-current status Nucl. Med. Biol. 1993, 20, 503-525
59. Pettigrew, J. D.; Freeman, R. P.; Wilson, P. D. Total synthesis of (-)-xyloketal D and its enantiomer-confirmation of absolute stereochemistry Can. J. Chem. 2004, 82, 1640-1648
60. Bischoff, C. A. Studien über Verkettungen. XXVI. Das Aethylanilin Ber. Dtsch. Chem. Ges. 1897, 30, 3178-3180
61. Garnier, E.; Blanchard, S.; Rodriguez, I.; Jarry, C.; Léger, J.-M.; Caubère, P.; Guillaumet, G. New access to oxazolopyridines via hydroxyamidine derivatives; application to quinolines Synthesis 2003, 2033-2040
62. Körner, M. Ueber das Benzoyl- o -Amidobenzamid J. Prakt. Chem. (Leipzig) 1887, 36, 155-165